Xenon Pharmaceuticals Inc. XENE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
6.89
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $7.5M | -$345.9M | — | -$279.9M | $581.8M |
| 2024 | $0 | -$234.3M | — | -$184.5M | $754.9M |
| 2023 | $0 | -$182.4M | — | -$156.7M | $927.9M |
| 2022 | $9.4M | -$125.4M | — | -$103.9M | $721.5M |
| 2021 | $18.4M | -$78.9M | — | -$71.6M | $550.0M |
| 2020 | $32.2M | -$28.8M | — | -$50.8M | $171.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| PATOU GARY | director | 2026-06-05 | Sell | 1,322 | $53.14 |
| Cannon Gillian | director | 2026-06-05 | Sell | 1,190 | $53.14 |
| PATOU GARY | director | 2026-06-01 | Option exercise | 2,645 | — |
| Machado Patrick | director | 2026-06-01 | Option exercise | 2,645 | — |
| Gover Justin D. | director | 2026-06-01 | Option exercise | 2,645 | — |
| GAROFALO ELIZABETH A. | director | 2026-06-01 | Option exercise | 2,645 | — |
| GANNON STEVEN | director | 2026-06-01 | Option exercise | 2,645 | — |
| GANNON STEVEN | director | 2026-06-01 | Tax withheld | 1,416 | $53.41 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.89 (safe)
- Working capital / assets 0.819
- Retained earnings / assets -1.967
- EBIT / assets -0.589
- Equity / liabilities 11.318
Source: SEC EDGAR filings · CIK 0001582313 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.